2020 官网升级中！现在您访问官网的浏览器设备分辨率宽度低于1280px请使用高分辨率宽度访问。
Disease Area
Product
Modality
Target
Discovery
IND
Ph I
Ph II
PhIII/Pivotal
BLA
Approval
Anbainuo®
1.A recombinant fusion protein of the type II TNF receptor. World's first applied biologics in rheumatology and immunology.
2.Launched in 2015, the first fusion protein-based biologic to be marketed in Zhejiang Province.
3.A total of 1,713 patients were enrolled in Ph2 and Ph3 clinical trials and the results have been published in SCI journals, making it the largest RCT study of Etanercept in China.
Fusion protein
TNFα
Anjianning®
1.A recombinant fully human anti-tumor necrosis factor (TNF) alpha monoclonal antibody, the biosimilar of world’s bestselling prescription Humira with the largest number of indications and sales in the treatment area of autoimmune disorders. The sales are significantly leading ahead of other products
2.Launched in 2019, the first adalimumab biosimilar in Zhejiang, a major new drug project in China
3.The Ph3 clinical trial enrolled a total of 648 patients, which is the largest Ph3 trial of Adalimumab in China
4.Anjianning® prescriptions with independent intellectual property rights, granted by Chinese and Russian patents
mAb
TNFα
Anshuzheng®
1.An orally available, small-molecule inhibitor of Janus kinase (JAK) enzymes.
2.Small-molecule targeted drug that is recommended at the forefront of authoritative national and international guidelines, on par with biologics
3.Launched in 2021
Small molecule
JAK
Anbaite®
1. A human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α), the first biological drugs used in IBD in China
2. Launched in 2021, its lyophilized and liquid formulations are protected by international patents.
3. Third commercialized large molecule drug after Anbainuo® and Anjianning®(Adalimumab)
4. A total of 337 patients were enrolled in the Phase III clinical trial to evaluate the efficacy, pharmacokinetics, immunogenicity and safety
mAb
TNFα
HS628
Biosimilar of Tocilizumab
mAb
IL-6R
Anruixi®
China's first CD20 antibody class I innovative drug. A human-mouse chimeric monoclonal antibody targeting CD20 on the surface of B-cell, leading to B-cell elimination via ADCC and CDC effect. Compared with other anti-CD20 mAbs, HS006 has stronger ADCC effect and volume of distribution at steady state (Vss), which leads to prolongated B-cell elimination and better efficacy
mAb
CD-20
BR201
Biosimilar of Secukinumab
mAb
IL-17A
TO TOP
